Lymphatica Medtech closes €17.9M Series B funding round to drive Innovation in Lymphedema Treatment

October 8, 2024

Lausanne, October 8th, 2024 – Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide. First of its kind, LymphoDrain is easy to implant subcutaneously through a minimally invasive technique and it’s intended to provide unprecedent benefits to patients by locally and actively replacing the lymphatic vessels draining function.

The funding round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this round.

To support its growth, Lymphatica has also opened a subsidiary in Italy to expand its R&D efforts and manage manufacturing and clinical operations.

Lymphatica is further strengthened by the appointment of Dan Rose as the new Chairman of the Board; Rose brings extensive leadership experience from LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical, and Medtronic. Additionally, Alessio Beverina, Managing Partner at Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next, have joined the Board of Directors, alongside existing independent board member Nanci Govinder.

We are thrilled to have closed our Series B financing, which will enable us to advance the clinical development of our groundbreaking technology for lymphedema patients. With the support of our investors and new board members, we are one step closer to delivering a transformative solution that will significantly improve the lives of those suffering from lymphedema.

Marco Pisano, CEO and co-founder of Lymphatica Medtech

Millions of people live with chronic lymphedema, and current treatment options fall short of providing effective relief. This investment allows us to continue advancing our LymphoDrain device, which has already shown promising results in a pilot feasibility study.

Valentina Triacca, COO and co-founder of Lymphatica Medtech

Lymphatica has made impressive progress in developing a compelling technology that has the potential to transform care and improve the lives of the many patients suffering from Lymphedema today. It is a privilege to join the Board as Chairman and to support the efforts of this great team.

Dan Rose

Lymphatica is addressing a massive unmet medical need, with over 10 million people affected by lymphedema. This technology has the potential to transform the lives of those patients.

Alessio Beverina, Managing Partner at Panakès

With its technology, Lymphatica is well-positioned to bring true sustainable clinical innovation in the treatment of lymphedema, greatly benefiting patients, physicians, and healthcare systems in various countries around the world.

Lukas Guenther, CIO of TechWald

About Lymphatica Medtech
Lymphatica Medtech is a Swiss medical device company founded in July 2017. It is a spin-off of the Swiss Federal Institute of Technology, Lausanne (EPFL) and of the Lausanne University Hospital (CHUV). The Company vision is to become the leader in the development and marketing of innovative medical devices for the treatment of lymphatic diseases. The company has developed LymphoDrain, a breakthrough implantable device designed to treat lymphedema. LymphoDrain is easy to implant subcutaneously through a minimally invasive technique and it’s intended to provide unprecedent benefits to millions of lymphedema patients worldwide, by locally and actively replacing the lymphatic vessels draining function.
More about Lymphatica Medtech SA

Contact information
Lymphatica Medtech SA
EPFL Innovation Park Bâtiment E
1015 Lausanne – Switzerland
contact@lymphatica.ch

About Panakès Partners
Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250 million under management.
More about Panakes

About TechWald Holding S.p.A
TechWald Next S.p.A. is an Operational Holding Company supporting high growth potential early-stage companies committed to develop Healthcare Innovation. TechWald has a key strategic focus on the MedTech industry and medical devices, equipment, digital devices which can provide benefit and value for Patients, Doctors, and Healthcare Systems.
More about TechWald

About Digital Transition Fund (PNRR) – CDP Venture Capital SGR S.p.A.
CDP Venture Capital is an asset management company fostering innovation and economic development in Italy. CDP Venture Capital supports innovative companies at all stages of their growth through both direct and indirect investments. The Digital Transition Fund (PNRR) invests in small and medium-sized enterprises that implement innovative solutions, particularly in the areas of artificial intelligence, cloud computing, healthcare, Industry 4.0, cybersecurity, fintech, blockchain, microelectronics, and other fields related to digital transition.
More about CDP Venture Capital

About OCCIDENT
OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards and enables founding teams to achieve outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and accompanies their portfolio companies over the long term.
More about OCCIDENT

About Zürcher Kantonalbank (ZKB)
Zürcher Kantonalbank is a leading universal bank in the Greater Zurich Area, with national roots and international reach. As one of the largest and most active investors in Switzerland, Zürcher Kantonalbank finances innovative start-ups with venture capital across various sectors, providing financial backing and strategic guidance.
More about Zürcher Kantonalbank

About Club Degli Investitori
The Club degli Investitori is an association composed of over 400 entrepreneurs, executives, and professionals who support startups and scale-ups founded by Italian entrepreneurs worldwide. An investment through the Club is much more than just capital: it involves the engagement of a group of international business angels whose network of contacts and experience is far more valuable than the financial resources alone. The Club has invested over €60 million in more than 70 companies, which have collectively raised over €2 billion and created over 6,500 jobs.
More about Degli Investitori

About HTGF – High-Tech Gründerfonds 
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 750 start-ups and successfully sold shares in more than 180 companies.  
Fund investors in the public-private partnership include the German Federal Ministry of Economics and Climate Action, KfW Capital and 45 companies.  
For more information, please visit HTGF.de or follow us on LinkedIn.  

Media contact
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
t.jacob@htgf.de